HK Stock Market Move | GIANT BIOGENE (02367) drops by more than 3% again, facing short-term pressure for recovery. Multiple institutions have lowered the company's performance forecast.

GIANT BIOGENE (02367) fell more than 3% again, as of the time of writing, it dropped by 2.93% to HK $35.14, with a turnover of HK $2.36 billion. On the news front, GIANT BIOGENE's sales were under pressure during the Double Eleven period. According to management data, sales of the Comfy brand on Tmall and Douyin decreased by 20% and 50% respectively year-on-year. Zhong Yin International released a research report stating that due to the short-term pressure on Ke Fu Mei, the company's revenue forecast for 2025/26 was revised down to -3.5% and 13.6%. The report pointed out that during the Double Eleven period, the company's sales were under pressure mainly due to Dabao's sales performance falling short of expectations. CITIC SEC released a research report stating that affected by the overall industry environment and company operational decisions, GIANT BIOGENE's Double Eleven sales were under pressure, leading to downward revisions in revenue and profit forecasts for 2025; meanwhile, the company's brand assets are solid, and there are structural highlights in operations. Looking ahead, the company has a clear short, medium, and long-term strategy, with Ke Fu Mei setting a target of billions in revenue and formulating clear plans in terms of products, operations, and channels, while Ke Li Jin is expected to create a second OTC explosive brand while pushing for brand reshaping.